Rayner unveils revolutionary Sophi Phaco system in the US
Posted on 14/01/2026
Rayner has secured US Food and Drug Administration (FDA) 510(k) clearance for Sophi, the Swiss-engineered phacoemulsification system set to redefine efficiency for US cataract surgeons.
Sophi (Swiss Ophthalmology Innovation) brings a bold new philosophy to the operating room: maximum productivity, without compromise. Packed with features tailored to meet the demands of ASCs, office-based surgery and US hospital networks alike – such as Triple Pump Fluidics (both peristaltic and venturi), an intuitive user interface and wireless power concept – Sophi is engineered for streamlined workflows. Surgeons and clinical teams benefit from faster setup, quicker patient turnover and greater mobility, without sacrificing patient safety.
The system has already earned strong global acclaim: “Sophi has been my only phaco machine for the past four years,” said Dr. Erik Mertens, Medical Director at Medipolis, Belgium, and Past-President of AECOS Europe. “Its fluidics, ease of use and versatility truly set it apart. I highly recommend it to high-volume cataract and refractive surgeons.”
Beyond performance, Sophi is prepared for the future of sustainable ophthalmology. A recent position paper from leading ophthalmic societies (ASCRS, ESCRS, APACRS, LATAMSCRS) estimated a 307kg reduction in discarded plastic per 1,000 cataract surgeries using Sophi’s day cassette option1. Rayner is committed to bringing this highly popular feature to the US market soon, supporting the industry’s drive to reduce surgical waste and carbon footprint.
Rayner CEO Tim Clover commented, “US surgeons deserve an innovative alternative to conventional phaco technology, and Sophi delivers that. Clinics worldwide tell us they’re running more efficiently and cutting cost and waste, so we’re looking forward to bringing these benefits to surgeons across the US through our new team of surgical equipment specialists”.
Contact your local Rayner representative for more information, or visit www.rayner.com/sophi
References
- The Unmet Need for Multiuse Phacoemulsification Machine Products Multisociety Position Paper. Multiuse Phaco Cassettes
About Rayner:
Since the implantation of the first Rayner intraocular lens by Sir Harold Ridley in 1949, Rayner has had the goal to improve vision and restore sight worldwide. Today, Rayner’s mission remains to deliver innovative and clinically superior ophthalmic products that respond to the expectations of our global customers to improve the sight and quality of life of their patients.
Headquartered in Worthing, United Kingdom, Rayner markets its medical devices, pharmaceuticals, and digital solutions globally through a network of distributors and includes direct sales teams in the United Kingdom, Eire, USA, Canada, Brazil, India, Poland, Australia, Germany, Austria, Switzerland, France, Italy, Spain, and Portugal.
Not all Rayner products are approved for sale in every country. Please contact your local Rayner distributor for details of which products are available in your area.
©2026 Rayner Group, all rights reserved. ‘Rayner’ and ‘Sophi’ are proprietary marks of the Rayner Group. All other trademarks are property of their respective owners. Rayner, The Ridley Innovation Centre, 10 Dominion Way, Worthing, West Sussex, BN14 8AQ. Registered in England: 615539 | EC 2026-03 EN